Study on the safety and efficacy of autologous platelet-rich plasma (PRP) in treatment of female stress urinary incontinence - Study on the safety and efficacy of autologous platelet-rich plasma (PRP) in treatment of female stress urinary incontinence

Abe Hirokazu0 sites40 target enrollmentOctober 16, 2023

Overview

No summary available.

Registry

who.int

Start Date

October 16, 2023

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

Female

Sponsor

Abe Hirokazu

•1\. Stress urinary incontinence
•2\. Female whose consent acquisition date is more than 20 years and less than 85 years
•3\. Patients who can appropriately evaluate pain from start of screening to the end of observation
•4\. Patients who have received sufficient explanation using ICF and understand the contents, and who have obtained written consent to participate in the study group based on their free will
•5\. Patients who can follow the scedule established until the end of the examination period

•1\. Patients who have a skin disease or infection at the administration site on the day of screening test or autologous platelet\-rich plasma (PRP) administration, and who are at risk of infection due to injection
•2\. Patients with a history or complication of malignancy within 5 years before obtaining consent
•3\. Patients with more than 150 ml of residual urine
•4\. Patients with platelet abnormalities
•5\. Patients taking anticoagulants
•6\. Patients with thrombosis
•7\. Patients with hypofibrinogenemia
•8\. Patients with hemodynamic instability
•9\. Patients with sepsis
•10\. Patient with anemia